Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study.

@article{LloydStill2006BioavailabilityAS,
  title={Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study.},
  author={John D. Lloyd-Still and Catherine A Powers and Dennis R. Hoffman and Katherine Boyd-Trull and Lucille A. Lester and Diane C Benisek and Linda M. Arterburn},
  journal={Nutrition},
  year={2006},
  volume={22 1},
  pages={36-46}
}
OBJECTIVE Several studies have reported omega-3 and omega-6 fatty acid imbalances in patients with cystic fibrosis (CF). Whether these imbalances contribute to or are manifestations of the pathophysiology of CF is unknown. The study objective was to determine bioavailability, tissue accretion, and safety of a large dose of an algal source of docosahexaenoic acid (DHA) triacylglycerol and to observe effects on lung function in patients with CF. METHODS Twenty subjects with CF (8 to 20 y of age… CONTINUE READING
17 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…